Ticiana Batista
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Ticiana Batista
May 24, 2024, 14:15 |
Blog
ACS Journal Cancer Editor-in-Chief, Suresh S. Ramalingam, is sharing the primary results of the phase 3 LAURA trial at ASCO
ACS Journal Cancer shared the following on X: “Our Editor-in-Chief, Suresh S. Ramalingam, is sharing the…
May 20, 2024, 07:20 |
Insight
Florez Lab: ACS Journal Cancer highlights the Florez Lab's Pregnancy and Lung Cancer Registry
Florez Lab shared a post by ACS Journal Cancer, on X "Thank you to ACS…
May 14, 2024, 16:28 |
Blog
Christian Rolfo: Great editorial by Ticiana Batista and Suresh S. Ramalingam on 20 years of EGFR
Christian Rolfo, Associate Director Clinical Research Center of Thoracic Oncology at The Tisch Cancer Institute…
Feb 7, 2024, 12:46 |
Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
All:
4
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube